Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Friedel

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Trends in Biotechnology|October 27, 2015
Surface-Engineered Viral Vectors for Selective and Cell Type-Specific Gene DeliveryChristian J Buchholz, Thorsten Friedel, Hildegard Büning
Plos Pathogens|June 10, 2016
Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell AttachmentRuben R Bender, Anke Muth, Irene C Schneider, et al.
Protein Engineering, Design & Selection : PEDS|February 27, 2015
Receptor-targeted lentiviral vectors are exceptionally sensitive toward the biophysical properties of the displayed single-chain FvThorsten Friedel, Lydia J Hanisch, Anke Muth, et al.
Biomaterials|August 22, 2017
Covalent coupling of high-affinity ligands to the surface of viral vector particles by protein trans-splicing mediates cell type-specific gene transferAlexander Muik, Johanna Reul, Thorsten Friedel, et al.
Stem Cells and Development|March 10, 2016
CD30 Receptor-Targeted Lentiviral Vectors for Human Induced Pluripotent Stem Cell-Specific Gene ModificationThorsten Friedel, Sabine Jung-Klawitter, Attila Sebe, et al.
Nature Communications|February 11, 2015
Off-target-free gene delivery by affinity-purified receptor-targeted viral vectorsRobert C Münch, Anke Muth, Alexander Muik, et al.
Oncotarget|March 22, 2018
CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphomaJulia D S Hanauer, Benjamin Rengstl, Dina Kleinlützum, et al.
Molecular Therapy Oncolytics|April 28, 2016
Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptorsJan Rh Hanauer, Lisa Gottschlich, Dennis Riehl, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Trends in Biotechnology|October 27, 2015
Surface-Engineered Viral Vectors for Selective and Cell Type-Specific Gene DeliveryChristian J Buchholz, Thorsten Friedel, Hildegard Büning
Plos Pathogens|June 10, 2016
Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell AttachmentRuben R Bender, Anke Muth, Irene C Schneider, et al.
Protein Engineering, Design & Selection : PEDS|February 27, 2015
Receptor-targeted lentiviral vectors are exceptionally sensitive toward the biophysical properties of the displayed single-chain FvThorsten Friedel, Lydia J Hanisch, Anke Muth, et al.
Biomaterials|August 22, 2017
Covalent coupling of high-affinity ligands to the surface of viral vector particles by protein trans-splicing mediates cell type-specific gene transferAlexander Muik, Johanna Reul, Thorsten Friedel, et al.
Stem Cells and Development|March 10, 2016
CD30 Receptor-Targeted Lentiviral Vectors for Human Induced Pluripotent Stem Cell-Specific Gene ModificationThorsten Friedel, Sabine Jung-Klawitter, Attila Sebe, et al.
Nature Communications|February 11, 2015
Off-target-free gene delivery by affinity-purified receptor-targeted viral vectorsRobert C Münch, Anke Muth, Alexander Muik, et al.
Oncotarget|March 22, 2018
CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphomaJulia D S Hanauer, Benjamin Rengstl, Dina Kleinlützum, et al.
Molecular Therapy Oncolytics|April 28, 2016
Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptorsJan Rh Hanauer, Lisa Gottschlich, Dennis Riehl, et al.
Pageof 1